Beyond metabolic control: the potential role of antidiabetic therapies in modulating male reproductive function and spermatogenesis.

The emerging role of glucagon-like peptide-1 receptor agonists in male infertility: mechanisms, experimental evidence, and future clinical perspectives

Overall, GLP-1RAs appear to be a promising therapeutic approach for treating obesity-related male reproductive dysfunction by acting on both metabolic health and possibly restoring reproductive function, but there is not enough evidence at present to justify the recommendation of GLP-1RAs as established fertility-enhan...

Irisin as a metabolic regulator of male reproduction.

Obesity and metabolic syndrome are major contributors to male infertility. These conditions disrupt the hypothalamic-pituitary-gonadal (HPG) axis and compromise testicular steroidogenesis and spermatogenesis through mechanisms that include altered aromatase activity, insulin resistance, chronic inflammation, and oxidat...

[Research progress on the role and mechanism of ketogenic diet in regulating gametogenesis].

Phytochemical–SGLT2 Inhibitor Combinations in Type 2 Diabetes: Mechanistic Complementarity, Preclinical Evidence and Translational Perspectives

Type 2 diabetes mellitus (T2DM) is a multifactorial metabolic disorder in which insulin resistance, progressive impairment of pancreatic β-cell function, abnormal hepatic glucose production and disturbances in lipid metabolism contribute to persistent hyperglycemia. Sodium-glucose cotransporter 2 (SGLT2) inhibitors hav...

Repurposing SGLT2 Inhibitors Beyond Diabetes: Emerging Roles in Cancer Prevention and Therapy.

Melatonin and Diabetic Nephropathy: From Mechanistic Pathways to Translational Opportunities in Clinical Management.

INTRODUCTION/OBJECTIVE Diabetic Nephropathy (DN) remains a leading cause of end-stage renal disease worldwide, characterized by a complex interplay of oxidative stress, chronic inflammation, and circadian rhythm disruption. Despite standard-of-care treatments like RAS inhibitors and newer agents like SGLT2 inhibitors a...